ALIM
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
9.95M
GET INTRADAY SIGNALS
ALIM Trading results, last 6 months
AI Robots NameP/LEntry Price, $Profit, $/%
40 days until earnings call
+Compare
ALIM
Stock ticker:
NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
9.95M

ALIM Price Prediction, Alimera Sciences AI Recommendations

Stock market charts, price targets, analyst ratings and a financial calendar

GET INTRADAY SIGNALS
ALIM Trading results, last 6 months
AI Robots NameP/LEntry Price, $Profit, $/%
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
AI
A.I.Advisor
a Summary for AAPL with price predictions
12:00 AM EDT Mar 23, 2023

ALIM in upward trend: price expected to rise as it breaks its lower Bollinger Band on March 10, 2023

ALIM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 40 of 46 cases where ALIM's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where ALIM advanced for three days, in of 226 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALIM declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for ALIM entered a downward trend on March 23, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (6.765). P/E Ratio (15.798) is within average values for comparable stocks, (48.055). ALIM's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.964). ALIM has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.026). P/S Ratio (0.183) is also within normal values, averaging (87.845).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ALIM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALIM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

AI
A.I. Advisor
published Earnings

ALIM is expected to report earnings to fall 55.33% to -33 cents per share on March 23

Alimera Sciences ALIM Stock Earnings Reports
Q4'22
Est.
$-0.34
Q3'22
Missed
by $0.35
Q2'22
Beat
by $0.22
Q1'22
Missed
by $0.11
Q4'21
Missed
by $0.17
The last earnings report on November 14 showed earnings per share of -75 cents, missing the estimate of -40 cents. With 6.02K shares outstanding, the current market capitalization sits at 9.95M.
AI
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are ZOETIS (NYSE:ZTS), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Intra-Cellular Therapies (NASDAQ:ITCI), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), Tilray Brands (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Avadel Pharmaceuticals plc (NASDAQ:AVDL), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 2.1B. The market cap for tickers in the group ranges from 246 to 77.31B. MKKGY holds the highest valuation in this group at 77.31B. The lowest valued company is PEMTF at 246.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was -1%. For the same Industry, the average monthly price growth was -11%, and the average quarterly price growth was -5%. VFRM experienced the highest price growth at 54%, while CHALF experienced the biggest fall at -83%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was -39%. For the same stocks of the Industry, the average monthly volume growth was -22% and the average quarterly volume growth was -64%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 54
P/E Growth Rating: 71
Price Growth Rating: 55
SMR Rating: 85
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
AI
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
AI
A.I.Advisor
published price charts
AI
A.I. Advisor
published General Information

General Information

a developer of ophthalmic pharmaceuticals

Industry PharmaceuticalsOther

Profile
Fundamentals
Details
Industry
Biotechnology
Address
6310 Town Square
Phone
+1 678 990-5740
Employees
154
Web
https://www.alimerasciences.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BOOT73.510.25
+0.34%
Boot Barn Holdings
KIM17.51-0.06
-0.34%
Kimco Realty Corp
VRM0.87-0.02
-1.70%
Vroom
INTR1.40-0.11
-7.28%
Inter & Co
NSPR1.09-0.09
-7.63%
InspireMD

ALIM and

Correlation & Price change

A.I.dvisor tells us that ALIM and ACET have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ALIM and ACET's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALIM
1D Price
Change %
ALIM100%
+5.19%
ACET - ALIM
29%
Poorly correlated
-3.18%
DVAX - ALIM
27%
Poorly correlated
+1.66%
OGI - ALIM
25%
Poorly correlated
+0.81%
DERM - ALIM
25%
Poorly correlated
-9.21%
EVO - ALIM
23%
Poorly correlated
-0.05%
More